Seventure Partners

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.